Canagliflozin vs Durvalumab

Canagliflozin vs Durvalumab: Overview

This comparison examines the pharmacological differences between Canagliflozin and Durvalumab.

Mechanism of Action

Canagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Canagliflozin — 10.6 hours; Durvalumab — 17 days.

Chemical Properties

Molecular Formula: Canagliflozin — C24H25FO5S.

Molecular Weight: Canagliflozin — 444.5170 g/mol.

Type: Canagliflozin — Small molecule; Durvalumab — Antibody.